Gentler chemo tested for elderly cancer patients
NCT ID NCT07125183
Summary
This study is testing whether giving a lower dose of the chemotherapy drug doxorubicin weekly, instead of the standard higher dose every few weeks, can help control advanced sarcoma in patients aged 65-100 while causing fewer side effects. Researchers will see if this gentler schedule can keep the cancer from growing for at least 12 weeks and will closely monitor patients' quality of life and safety. The trial also aims to learn how this treatment might affect the immune system's response to the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.